Aneyefor News

(Albany, US) On November 04, 2026, DelveInsight’s “Postpartum Depression Market Insights, Epidemiology and Market Forecast – 2036” report provides comprehensive insights into the Postpartum Depression (PPD) market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, and examines the market drivers and barriers shaping the space.

Discover the latest drugs and treatment options in the Postpartum Depression Market @ https://www.delveinsight.com/report-store/postpartum-depression-ppd-market

Key Takeaways from the Postpartum Depression Report

• In May 2026, Reunion Neuroscience presented full results from the Phase II RECONNECT trial of luvesilocin in adults with moderate-to-severe PPD at the ASCP 2026 Annual Meeting. The company expects to start a pivotal Phase III trial in 2026, and the drug holds FDA Breakthrough Therapy Designation.

• In April 2026, Lipocine announced topline Phase III results for LPCN 1154. The drug did not show a statistically significant reduction in HAM-D17 total score versus placebo at hour 60, missing the primary endpoint, though it was well tolerated. The data were selected for presentation at ASCP 2026.

• In November 2025, TWi Biotechnology reported that its Phase II trial of NORA520 did not show a statistically significant difference versus placebo in the combined treatment groups.

• In July 2025, Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics. In April 2025, the FDA withdrew approval for brexanolone (Zulresso) at Sage’s request, for commercial reasons.

• Zuranolone (ZURZUVAE), developed by Sage and Biogen, is the first and only FDA-approved oral medicine for PPD, approved in August 2023 as a 14-day oral course.

• DelveInsight estimates about 1.3 million diagnosed prevalent PPD cases in the 7MM in 2025, including about 700,000 in the US and about 100,000 in Japan.

• DelveInsight’s report depicts a space moving from conventional antidepressants toward rapid-acting neuroactive steroids and novel mechanisms.

• Leading Postpartum Depression companies include Sage Therapeutics, Biogen, Reunion Neuroscience, Lipocine, TWi Biotechnology, and others.

• Promising therapies include zuranolone (ZURZUVAE), luvesilocin (RE104), LPCN 1154, NORA520, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Postpartum Depression Treatment Drugs

Postpartum Depression Overview

PPD is a serious mood disorder that occurs during pregnancy or, more commonly, in the weeks to months after childbirth. Unlike the transient “baby blues,” it is more severe and can significantly impair a mother’s ability to care for herself and her child. It is thought to result from hormonal fluctuations, genetic predisposition, psychosocial stressors, prior psychiatric history, and environmental factors. Diagnosis is clinical, using history, symptom assessment, and screening tools such as the Edinburgh Postnatal Depression Scale, PHQ-9, and DSM-5 criteria. Mild-to-moderate cases are managed with psychotherapy, while moderate-to-severe cases may need antidepressants, with SSRIs the usual first choice. PPD-specific neuroactive steroid therapy now offers faster symptom improvement.

Common symptoms include:

• Persistent sadness, anxiety, and hopelessness

• Irritability and fatigue

• Sleep disturbances

• Impaired concentration

• Difficulty bonding with the infant

Postpartum Depression Emerging Drugs Profile

Luvesilocin (RE104): Reunion Neuroscience Luvesilocin is a proprietary prodrug of 4-OH-DiPT, a serotonin 5-HT2A receptor agonist given by subcutaneous injection. It is a serotonergic neuroplastogen designed to produce rapid, durable antidepressant effects after a single administration. In the Phase II RECONNECT trial in moderate-to-severe PPD, it showed a robust decrease in depression symptoms and was generally well tolerated. It holds FDA Breakthrough Therapy Designation, and a pivotal Phase III trial is expected to start in 2026. Currently, the drug is in late-stage planning for Phase III.

LPCN 1154: Lipocine LPCN 1154 is oral brexanolone, a GABA-A receptor modulator chemically identical to the endogenous hormone allopregnanolone, aimed at rapid, at-home rescue therapy for PPD without intensive monitoring. In April 2026, the Phase III trial missed its primary endpoint on the HAM-D17 score versus placebo, although the drug was well tolerated. Currently, the drug is in Phase III.

NORA520: TWi Biotechnology NORA520 is an oral investigational neuroactive steroid and GABA-A receptor modulator for PPD. In November 2025, the Phase II trial did not show a statistically significant difference versus placebo in the combined treatment groups. Currently, the drug is in Phase II.

Explore groundbreaking therapies and clinical trials in the Postpartum Depression Pipeline @ Postpartum Depression Treatment Drugs

Postpartum Depression Market Drivers

• Maternal mental health screening: Routine depression screening in pregnancy and the postpartum period supports earlier identification and higher treatment uptake.

• Growing patient pool: About 1.3 million diagnosed prevalent cases in the 7MM in 2025 are expected to rise through the forecast period.

• Demand for rapid symptom relief: Conventional antidepressants can take weeks, so fast-acting therapies address a critical need.

• First-mover success of zuranolone: Its approval and growing physician familiarity, with about 80% of prescriptions from OBGYNs, show the potential of the neuroactive steroid class.

• Novel pipeline mechanisms: Serotonergic neuroplastogens and next-generation GABA-A modulators aim for faster, more durable, and more convenient treatment.

• Regulatory support: Breakthrough Therapy Designation for luvesilocin may speed development.

• Broader payer coverage and savings programs: Increasing coverage and programs such as the ZURZUVAE Savings Card support access.

Learn about new drugs, pipeline developments, and key players with DelveInsight’s expert analysis @ Postpartum Depression Market Drivers and Barriers

Postpartum Depression Market Barriers

• Recent pipeline setbacks: LPCN 1154 and NORA520 missed their primary endpoints, which tempers confidence in the neuroactive steroid class.

• Entrenched low-cost standard of care: Psychotherapy and generic SSRIs remain first-line and widely used.

• Underdiagnosis and stigma: Many women with PPD remain undiagnosed or untreated, and disparities in access persist.

• Limited biomarkers: There are few objective diagnostic tools or predictors of response.

• Safety and monitoring concerns: Breastfeeding considerations and the need for infant-safe, at-home options constrain development.

• Corporate changes: Sage’s acquisition and brexanolone’s withdrawal show the commercial difficulty of this space.

• Concentrated pipeline: Only one candidate has a Phase III trial still to run, and the late-stage field is small.

Scope of the Postpartum Depression Report

• Coverage: 7MM (US, EU4, UK, Japan)

• Companies: As listed above

• Therapies: Zuranolone (ZURZUVAE), luvesilocin (RE104), LPCN 1154, NORA520, and others

• Assessment by Product Type: Mono, Combination, Mono/Combination

• Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Postpartum Depression report today! @ Postpartum Depression Companies

Table of Contents

1. Introduction

2. Executive Summary

3. Postpartum Depression: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III): LPCN 1154 (Lipocine); Luvesilocin/RE104 (Reunion Neuroscience), Phase III planned

8. Mid Stage Products (Phase II): NORA520 (TWi Biotechnology)

9. Early Stage Products (Phase I): None currently

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

19. About Us

About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432 NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting